Novartis to Acquire Endocyte for Expansion of its Investigational Radioligand Therapy (RLT) Platform

 Novartis to Acquire Endocyte for Expansion of its Investigational Radioligand Therapy (RLT) Platform

Novartis to Acquire Endocyte for Expansion of its Investigational Radioligand Therapy (RLT) Platform

Shots:

  • Endocyte to receive $24M/share in cash with total deal value of $2.1B. Novartis to get hold of all stocks with its RLT candidates Lu-PSMA-617 & Ac-PSMA-617
  • Lu-PSMA-617 is a novel treatment currently evaluated globally in P-III VISION clinical trial in men with mCRPC and demonstrated positive results in P-II (N=50) with mPFS (7.6 mos) & mOS (13.5 mos) in mCRPC
  • Additionally, Novartis gained rights for Lutathera (lutetium Lu 177 dotatate / INN: lutetium (177Lu) oxodotreotide) with acquisition of AAA, a novel approved Peptide Receptor Radionuclide Therapy for GEP-NETs

Click here to read full press release/ article | Ref: Novartis | Image: RTE

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post